{"id":"isofezolac","rwe":[{"pmid":"4029250","year":"1985","title":"Effect of probenecid on isofezolac kinetics.","finding":"","journal":"European journal of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"6500763","year":"1984","title":"The effect of antacid and aspirin on the bioavailability of isofezolac in man.","finding":"","journal":"International journal of clinical pharmacology, therapy, and toxicology","studyType":"Clinical Study"},{"pmid":"7391179","year":"1980","title":"Determination of isofezolac in biological fluids by reversed-phase liquid column chromatography.","finding":"","journal":"Journal of chromatography","studyType":"Clinical Study"}],"tags":[{"label":"isofezolac","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Osteoarthritis","category":"indication"},{"label":"Rheumatoid arthritis","category":"indication"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"sofenac","offLabel":[],"synonyms":["isofezolac","sofenac"],"timeline":[],"approvals":[],"brandName":"Sofenac","ecosystem":[{"indication":"Osteoarthritis","otherDrugs":[{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"celecoxib","slug":"celecoxib","company":"Gd Searle"},{"name":"choline magnesium trisalicylate","slug":"choline-magnesium-trisalicylate","company":""}],"globalPrevalence":655000000},{"indication":"Rheumatoid arthritis","otherDrugs":[{"name":"abatacept","slug":"abatacept","company":"Bristol Myers Squibb"},{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"}],"globalPrevalence":18000000}],"mechanism":{"modality":"Small Molecule","drugClass":"isofezolac","explanation":"When you have an injury or inflammation, your body produces chemicals called prostaglandins, which cause pain and swelling. Sofenac blocks the COX-2 enzyme, which is responsible for making these prostaglandins. By blocking this enzyme, Sofenac reduces the amount of prostaglandins produced, which in turn reduces pain and inflammation.","oneSentence":"Sofenac works by inhibiting the COX-2 enzyme, which reduces inflammation and pain.","technicalDetail":"Isofezolac is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), a key enzyme involved in the production of prostaglandins, which mediate inflammation and pain."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1492","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ISOFEZOLAC","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:10:19.788573","biosimilars":[],"competitors":[],"genericName":"isofezolac","indications":{"approved":[{"name":"Osteoarthritis","source":"DrugCentral","snomedId":396275006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":655000000,"prevalenceMethod":"curated","prevalenceSource":"Arthritis Res Ther, 2023 (PMID:36991481)"},{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"7K6U6T1360","CHEBI":"CHEBI:135494","INN_ID":"4438","UMLSCUI":"C0124087","ChEMBL_ID":"CHEMBL2104795","PUBCHEM_CID":"68677","MESH_SUPPLEMENTAL_RECORD_UI":"C020696"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"1985","pmid":"4029250","title":"Effect of probenecid on isofezolac kinetics.","journal":"European journal of clinical pharmacology"},{"date":"1984 Sep","pmid":"6500763","title":"The effect of antacid and aspirin on the bioavailability of isofezolac in man.","journal":"International journal of clinical pharmacology, therapy, and toxicology"},{"date":"1980 Jun 13","pmid":"7391179","title":"Determination of isofezolac in biological fluids by reversed-phase liquid column chromatography.","journal":"Journal of chromatography"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofenac (ISOFEZOLAC) is a small molecule drug in the isofezolac class, used to treat Osteoarthritis and Rheumatoid arthritis. Its exact target is unknown, but it is believed to work by inhibiting the enzyme COX-2, which plays a key role in inflammation. Sofenac is not FDA approved, and its commercial status is unclear. Key safety considerations include potential gastrointestinal side effects and cardiovascular risks. Further research is needed to fully understand its pharmacokinetics and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}